Koligo Therapeutics (ASX:KOL) Net Margin %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Koligo Therapeutics Net Margin %?

Koligo Therapeutics ASX:KOL Net Margin % is 0.00% as of . 20.

Net margin is calculated as Net Income divided by its Revenue. Koligo Therapeutics's Net Income for the six months ended in . 20 was A$0.00 Mil. Koligo Therapeutics's Revenue for the six months ended in . 20 was A$0.00 Mil. Therefore, Koligo Therapeutics's net margin for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Koligo Therapeutics's Net Margin % or its related term are showing as below:


ASX:KOL's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Koligo Therapeutics  (ASX:KOL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Koligo Therapeutics Net Margin % Related Terms

Koligo Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Koligo Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Koligo Therapeutics Net Margin % Chart

Koligo Therapeutics Annual Data
Trend
Net Margin %

Koligo Therapeutics Semi-Annual Data
Net Margin %

ASX:KOL vs : Net Margin % Comparison

For the Biotechnology subindustry, Koligo Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Koligo Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Koligo Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Koligo Therapeutics's Net Margin % falls into.


Koligo Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Koligo Therapeutics's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin=Net Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Koligo Therapeutics's Net Margin for the quarter that ended in . 20 is calculated as

Net Margin=Net Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Koligo Therapeutics (ASX:KOL) has a Net Margin % of 0.00% as of . 20. Net margin is the ratio of total net income to net sales. View historical data on Koligo Therapeutics and its competitors.
Is Koligo Therapeutics' Net Margin % too high?
Koligo Therapeutics' current Net Margin % is 0.00%.
How does Koligo Therapeutics' Net Margin % compare to ?
Koligo Therapeutics' Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Koligo Therapeutics and its competitors. Koligo Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koligo Therapeutics stock overvalued right now?
Koligo Therapeutics (ASX:KOL) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Koligo Therapeutics (ASX:KOL), the current Net Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Koligo Therapeutics Business Description

Comparable Companies